Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease
This elegant double-blind, placebo-controlled trial shows the addition of an ARB in patients with ADPKD already on an ACE inhibitor did not alter the decline in estimated GFR. Based on this evidence, there seems to be no role for dual RAAS blockade in this population.
:
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
The safety of combining angiotensin-converting-enzyme inhibitors with angiotensin-receptor blockers in elderly patients: a population-based longitudinal analysis
Retraction—Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial
Source: Nephrology Now - Category: Urology & Nephrology Authors: Nephrology Now editors Tags: Chronic Kidney Disease Polycystic Kidney Disease Source Type: research
More News: Chronic Kidney Disease | Diabetes | Endocrinology | Polycystic Kidney Disease | Urology & Nephrology